Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar trackjakeambrose (71.54) Submitted: 8/13/2012 10:44:10 PM : Outperform Start Price: $145.03 BIIB Score: +0.38

final decision was based on my friends ratings here at the fool

Featured Broker Partners


Advertisement